Sign in Sign up for free

Last updated: 8 June 2021 at 5:54pm EST

Richard Meelia Net Worth




The estimated Net Worth of Richard J Meelia is at least $3.5 Million dollars as of 4 February 2021. Mr. Meelia owns over 10,353 units of Haemonetics stock worth over $3,072,097 and over the last 19 years he sold HAE stock worth over $0. In addition, he makes $429,916 as Independent Chairman of the Board at Haemonetics.

Mr. Meelia HAE stock SEC Form 4 insiders trading

Richard has made over 5 trades of the Haemonetics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 10,353 units of HAE stock worth $367,532 on 4 February 2021.

The largest trade he's ever made was buying 45,454 units of Haemonetics stock on 25 July 2017 worth over $249,997. On average, Richard trades about 3,155 units every 43 days since 2005. As of 4 February 2021 he still owns at least 42,403 units of Haemonetics stock.

You can see the complete history of Mr. Meelia stock trades at the bottom of the page.





Richard Meelia biography

Richard J. Meelia serves as Independent Chairman of the Board of the Company. Mr. Meelia is currently a principal of Meelia Ventures, LLC, a private equity firm focused on early stage healthcare companies. From July 2007 until his retirement in July 2011, Mr. Meelia served as Chairman, President, and Chief Executive Officer of Covidien plc, a global healthcare company, following its separation from Tyco International in June 2007. Prior to that separation, Mr. Meelia served in a variety of senior leadership roles, including Chief Executive Officer and President of Tyco Healthcare. Mr. Meelia joined Kendall Healthcare Products Company, the foundation of both the Tyco Healthcare Business and Covidien, as Group President in 1991. Mr. Meelia previously served on the Board of Apollo Endosurgery, Inc. and served on the Company’s Board from 2005 to 2009. In addition to his public company board service, Mr. Meelia is a member of the Board of Trustees of St. Anselm College and Elms College and serves on the Board of two non-profit charities, Por Christo and St. Francis House. Having served as President and Chief Executive Officer of a large global healthcare company and having a long and decorated career in the healthcare industry, Mr. Meelia provides the Board many years of leadership experience in the field of global healthcare, including expertise in strategic planning, market development and international operations.

What is the salary of Richard Meelia?

As the Independent Chairman of the Board of Haemonetics, the total compensation of Richard Meelia at Haemonetics is $429,916. There are 5 executives at Haemonetics getting paid more, with Christopher Simon having the highest compensation of $9,398,200.



How old is Richard Meelia?

Richard Meelia is 71, he's been the Independent Chairman of the Board of Haemonetics since 2011. There are no older and 13 younger executives at Haemonetics.

Insiders trading at Haemonetics

Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy, and Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.



What does Haemonetics do?

haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right



What does Haemonetics's logo look like?

Haemonetics Corp. logo

Complete history of Mr. Meelia stock trades at Apollo Endosurgery Inc, Conformis, and Haemonetics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
4 Feb 2021 HAE Haemonetics Corp. Richard J Meelia
Director
 Option 10,353 $35.50 $367,532
4 Feb 2021
42,403 ↗
11 Nov 2019 HAE Haemonetics Corp. Richard J Meelia
Director
 Option 6,573 $45.45 $298,743
11 Nov 2019
36,640 ↗
14 Dec 2018 HAE Haemonetics Corp. Richard J Meelia
Director
 Option 8,196 $36.37 $298,089
14 Dec 2018
36,803 ↗
10 Aug 2017 HAE Haemonetics Corp. Richard J Meelia
Director
 Option 24,086 $33.39 $804,232
10 Aug 2017
34,029 ↗
25 Jul 2017 APEN Apollo Endosurgery Inc Richard J Meelia
Director
 Buy 45,454 $5.50 $249,997
25 Jul 2017
45,454 ↗


Haemonetics executives and stock owners

Haemonetics executives and other stock owners filed with the SEC include: